Vycor (OTCQB:VYCO) Signs Agreement with HealthSouth (NYSE:HLS) for Second NovaVision Therapy Product

Vycor (OTCQB:VYCO) Signs Agreement with HealthSouth (NYSE:HLS) for Second NovaVision Therapy Product

BOCA RATON, Florida - June 8, 2015 (Investorideas.com Newswire) - Vycor Medical, Inc. ("Vycor") (VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it has entered into an agreement with HealthSouth Corporation (NYSE:HLS) to make available its NeuroEyeCoach Professional Center therapy program to participating HealthSouth hospitals, following a 3-month trial of the therapy in two HealthSouth locations.

NeuroEyeCoach is NovaVision's eye movement compensation therapy for those patients who have suffered a cerebral visual field disorder as a result of a stroke or brain injury and is designed to improve a patient's ability to scan their environment more efficiently. The program is based on several decades of scientific research pioneered by Professor Josef Zihl at the Max Planck Institute in Munich that has been the subject of numerous clinical studies. Participating HealthSouth hospitals will use the program to treat patients while in their care. In contrast to other clinic-based saccadic programs, NeuroEyeCoach is a full-course therapy dedicated to cerebral visual field disorders and can be continued by the patient in their home environment.

This agreement follows the approval by HealthSouth in late 2014 to make available its VIDIT diagnostic to their hospital network and NovaVision is installing devices into this network. The NovaVision VIDIT is the diagnostic component of the Company's Vision Restoration Therapy (VRT) and is used to perform high-resolution visual field tests to screen for central visual field deficits commonly associated with stroke or brain injury. The ability for Health South physicians to be able to quickly identify visual disorders through the effective screening program is highlighted by the fact that approximately one-third of stroke or other brain injury patients suffer from a neurologically induced visual disorder and if this deficit goes undetected it may adversely impact other rehabilitation modalities. Early detection and treatment are critical steps towards improving overall patient care, a key objective of HealthSouth.

Once diagnosed, patients are able to be treated in-clinic with NeuroEyeCoach and referred to NovaVision for treatment following discharge at home using VRT, which is the only FDA cleared clinically supported therapy targeted at the restoration of lost vision resulting from neurological brain damage such as that resulting from stroke.

HealthSouth (www.healthsouth.com) is one of the largest providers of post-acute healthcare services in the U.S. These two agreements therefore provide NovaVision with a source of installation and rental income but equally as important is a potentially large source of patients; most stroke patients will touch a rehabilitation center at some point and HealthSouth is the largest network of stroke rehabilitation hospitals in the U.S.

This announcement follows NovaVision's press release in March that it had completed development of VRT 7.0, re-engineering the therapy to be internet-delivered and streamlining business process to enable a significant reduction in cost to the patient.

NovaVision will provide VRT and NeuroEyeCoach in one therapy suite. NovaVision will very shortly be commencing accepting patients with the new therapy suite which is considered by management to be the most affordable, clinically supported, comprehensive therapy suite available on the market to address visual disorders arising from stroke or brain injury.

Read this release in full http://www.investorideas.com/CO/VYCO/news/2015/06081.asp

About Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly traded company (VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical's ViewSite(TM) Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in Brazil, India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company's proprietary Visual Restoration Therapy(R) (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any Physician. VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed a therapy called NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to VRT(TM). The two therapies address different visual disabilities each of which results from neurologically-induced vision loss - a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Vycor Medical, Inc. Contacts:

6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

SOURCE: Vycor Medical, Inc.

For more information on VYCO on Investorideas, please visit: http://www.investorideas.com/CO/VYCO/

Visit this company: www.vycormedical.com, www.vycorvbas.com, www.novavision.com

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Vycor Medical Inc. (VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media and news distribution: Five thousand per month, one month with option to renew.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Vycor Medical, Inc. (VYCO) Company's NovaVision's Vision Restoration Therapy Featured in Radio Interview

Medical Technology Media Alert: Vycor Medical, Inc. (VYCO) Company's NovaVision's Vision Restoration Therapy Featured in Radio Interview

Patient Shares Success Story and How "It's the Only Option for Vision Therapy"

BOCA RATON, FL - June 4, 2015 (Investorideas.com Newswire) - Vycor Medical, Inc. ("Vycor") (VYCO), a provider of innovative and superior surgical and therapeutic solutions issues a media alert for NovaVision, one of its core business units. NovaVision was recently featured in radio interview with a patient discussing its unique neurostimulation therapy.

Former patient Carole Urban discusses her first-hand experience with Vision Restoration Therapy (VRT) on KSBT Radio FM 91.5 It's Your Health. Carole had had lost her sight as a result of brain damage incurred from a motorcycle accident and has regained her life after undertaking NovaVision's Vision Restoration Therapy (VRT).

Carole notes in the interview that she and her sister researched her options and that NovaVision's Vision Restoration Therapy was the only vision therapy they could find. Despite the skepticism of her physician, she says her vision was restored to 91% as a result of using it for six months.

Carole Urban was interviewed earlier this month on WYPL 89.3 FM Memphis, TN "Eye On Vision" Radio Show, the show reaches a large group of visually impaired listeners through the show's podcast. This interview was picked by the producer following hearing about Carole's ability to run again and pursue her hobbies since she got her vision back.

In April Carole had also been interviewed on iHeartRadio and WLBY 1290 on the Ann Arbor's Business Talk Radio, "The Lucy Ann Lance Radio Show". WLBY,"Ann Arbor's Talk Station carries nationally syndicated programs such as The Mike Huckabee Show, Geraldo Rivera, and John Bachelor.

NovaVision has the only commercially available, FDA cleared therapy underpinned by 15 years of research and clinical studies for the restoration of vision loss resulting from neurological brain damage of which Stroke and TBI are the most common causes.

Hear the radio interview: https://soundcloud.com/novavision-1/carole-urban-may-28

Read this release in full at http://www.investorideas.com/CO/VYCO/news/2015/06041.asp

About Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly traded company (VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical's ViewSite(TM) Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in Brazil, India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company's proprietary Visual Restoration Therapy(R) (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any Physician. VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed a therapy called NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to VRT(TM). The two therapies address different visual disabilities each of which results from neurologically-induced vision loss - a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Vycor Medical, Inc. Contacts:

6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

SOURCE: Vycor Medical, Inc.

For more information on VYCO on Investorideas, please visit: http://www.investorideas.com/CO/VYCO/

Visit this company: www.vycormedical.com, www.vycorvbas.com, www.novavision.com

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Vycor Medical Inc. (VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media and news distribution: Five thousand per month, one month with option to renew.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Aethlon Medical (OTCQB: AEMD) Expands Clinical Research Studies to Include Chikungunya Virus

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Expands Clinical Research Studies to Include Chikungunya Virus

SAN DIEGO - June 4, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that it has entered into an agreement with the National Institute of Virology (NIV) to begin testing of the Aethlon Hemopurifier® as a candidate to treat Chikungunya, a debilitating mosquito-borne virus that is not addressed with proven antiviral drug or vaccine therapies. In late 2013, Chikungunya was identified for the first time in the Americas on islands in the Caribbean. Since then, transmission of the virus has been identified in 44 countries or territories throughout the Americas with more than 1.2 million suspected cases reported to the Pan American Health Organization.

The NIV is one of the major institutes of the Indian Council of Medical Research (ICMR) and is a World Health Organization (WHO) collaborating center for arbovirus and hemorrhagic virus research. In previous NIV studies, the Aethlon Hemopurifier® was validated to capture Dengue virus from human blood serum.

The Aethlon Hemopurifier is an affinity biofiltration device that targets the rapid elimination of infectious viruses and cancer promoting exosomes from the circulatory system of treated individuals. In the treatment of infectious viral pathogens, the Hemopurifier provides a candidate solution for antiviral drug resistance and serves as a first-line countermeasure against viruses that are not addressed with proven drug therapies. To date, Hemopurifier therapy has been successfully administered to individuals infected with Ebola virus (Ebola), Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV).

A U.S. Food and Drug Administration (FDA) approved clinical study of Hemopurifier therapy is currently being conducted in HCV-infected end-stage renal disease patients. Additionally, Hemopurifier clinical protocols to treat Ebola virus have recently been approved by both the FDA and the Medical Devices Bureau of Health Canada.

Read this release in full at http://www.investorideas.com/CO/AEMD/news/2015/06041.asp

About Aethlon Medical, Inc.

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer promoting exosomes from the circulatory system of treated individuals. Our majority owned subsidiary Exosome Sciences, Inc., is advancing exosome-based liquid biopsies to diagnose and monitor Cancer and Chronic Traumatic Encephalopathy (CTE), a neurodegenerative disorder often found in individuals with a history of repetitive brain trauma.

About The Aethlon Hemopurifier®

Of the hundreds of viruses known to be infectious to man, antiviral drug therapies are approved for fewer than ten. The Aethlon Hemopurifier® provides a broad-spectrum therapeutic strategy to address drug resistant viral pathogens. To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus (Ebola), Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV). Time Magazine recently named the Hemopurifier to their list of 'Top 25 Inventions" and "The 11 Most Remarkable Advances in Healthcare." Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the capture of some of world's deadliest pathogens. These include: Dengue hemorrhagic fever, Lassa hemorrhagic fever, H5N1 avian influenza, H1N1 swine flu virus, the reconstructed 1918 influenza virus, West Nile virus and Vaccinia and Monkeypox, which serve as models for human smallpox infection. U.S. clinical progression of Hemopurifier therapy is being advanced under FDA approved clinical studies.

Aethlon is also investigating the use of Hemopurifier therapy to capture tumor-derived exosomes, a significant unaddressed therapeutic target in cancer care. Tumor-derived exosomes promote cancer progression through multiple mechanisms, which include seeding the spread of metastasis and direct suppression of the immune response. In regards to our therapeutic mechanism of action, the Hemopurifier incorporates a patented affinity technique that allows for selective binding to a unique structure that resides on the surface of tumor-derived exosomes and glycoproteins that coat infectious viruses. Additional information can be found online at www.AethlonMedical.com  or you can connect with us on on http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

James A. Joyce 
Chairman and CEO 
858.459.7800 x301 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer 
858.459.7800 x300 
jfrakes@aethlonmedical.com

David Zazoff 
MDM Worldwide Solutions 
646-403-3554

dzazoff@mdmworldwide.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Aethlon Medical (OTCQB: AEMD) to Present at SeeThruEquity Microcap Investor Conference

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) to Present at SeeThruEquity Microcap Investor Conference

SAN DIEGO - May 26, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Chief Executive Officer, will present at the SeeThruEquity 4th Annual Microcap Investor Conference on Thursday, May 28th. Details of Aethlon Medical's presentation are as follows:

Event: SeeThruEquity 4th Annual Microcap Investor Conference 
Date: Thursday, May 28, 2015 
Time: 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time 
Location: Convene Grand Central in Midtown Manhattan, New York

A live audio webcast of the presentation will be available on the Company's website (www.aethlonmedical.com) in the Investor Relations section on the Events and Presentations or can be accessed directly at http://wsw.com/webcast/seethru11/aemd.

About SeeThruEquity

SeeThruEquity ("STE") is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and unbiased. STE does not conduct any investment banking or commission based business. STE is approved to contribute research to Thomson Reuters One (First Call), CapitalIQ, FactSet, and Zacks, and distribute its research to its database of opt-in investors. Company research estimates are also contributed to Thomson Estimates, the leading estimates platform on Wall Street.

About Aethlon Medical, Inc.

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer promoting exosomes from the circulatory system of treated individuals. Our majority owned subsidiary Exosome Sciences, Inc., is advancing exosome-based liquid biopsies to diagnose and monitor Cancer and Chronic Traumatic Encephalopathy (CTE), a neurodegenerative disorder often found in individuals with a history of repetitive brain trauma.

About The Aethlon Hemopurifier®

Of the hundreds of viruses known to be infectious to man, antiviral drug therapies are approved for fewer than ten. The Aethlon Hemopurifier® provides a broad-spectrum therapeutic strategy to address drug resistant viral pathogens. To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus (Ebola), Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV). Time Magazine recently named the Hemopurifier to their list of 'Top 25 Inventions" and "The 11 Most Remarkable Advances in Healthcare." Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the capture of some of world's deadliest pathogens. These include: Dengue hemorrhagic fever, Lassa hemorrhagic fever, H5N1 avian influenza, H1N1 swine flu virus, the reconstructed 1918 influenza virus, West Nile virus and Vaccinia and Monkeypox, which serve as models for human smallpox infection. U.S. clinical progression of Hemopurifier therapy is being advanced under FDA approved clinical studies.

Aethlon is also investigating the use of Hemopurifier therapy to capture tumor-derived exosomes, a significant unaddressed therapeutic target in cancer care. Tumor-derived exosomes promote cancer progression through multiple mechanisms, which include seeding the spread of metastasis and direct suppression of the immune response. In regards to our therapeutic mechanism of action, the Hemopurifier incorporates a patented affinity technique that allows for selective binding to a unique structure that resides on the surface of tumor-derived exosomes and glycoproteins that coat infectious viruses. Additional information can be found online at www.AethlonMedical.com or you can connect with us on on http://www.aethlonmedical.com/and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

James A. Joyce 
Chairman and CEO 
858.459.7800 x301 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer 
858.459.7800 x300 
jfrakes@aethlonmedical.com

David Zazoff 
MDM Worldwide Solutions 
646-403-3554 
dzazoff@mdmworldwide.com

Visit this company: www.aethlonmedical.com

Disclaimer/ Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Aethlon Medical (AEMDD) Announces Health Canada Approval of Ebola Treatment Protocol

Medical Technology Breaking News: Aethlon Medical (AEMDD) Announces Health Canada Approval of Ebola Treatment Protocol

SAN DIEGO - May 13, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCQB:AEMD, AEMDD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to treat Ebola-infected individuals with the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class affinity biofiltration device designed for the broad-spectrum elimination of viral pathogens from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other life-threatening viruses that are not addressed with proven drug therapies. Health Canada is the Federal department responsible for overseeing the health of Canadian citizens.

The Health Canada approved protocol is entitled, "The Treatment of Ebola Virus Disease (EVD) in Humans with the Aethlon Hemopurifier Lectin Affinity Plasmapheresis Device". The protocol allows for an investigational study of Hemopurifier therapy to be conducted in up to 3 human subjects. The objective of the study is to standardize and evaluate the use of the Hemopurifier as supportive care in the treatment of EVD. There is no assurance that the investigational study will result in the collection of clinical data that would support Health Canada licensing requirements. Aethlon further disclosed that the Ebola study protocol had also been approved by the University Health Network (UHN) Research Ethics Board, based in Toronto, Ontario.

Previously, Aethlon disclosed that the United States (U.S.) Food and Drug Administration (FDA) approved a clinical protocol to treat Ebola-infected individuals with Hemopurifier therapy in the U.S. The Company has also submitted a Humanitarian Use Device (HUD) application with FDA to support potential market clearance of the Hemopurifier as a treatment for EVD.

The first administration of Hemopurifier therapy to an ebola-infected individual occurred at Frankfurt University Hospital in Germany. On November 14, 2014, the resulting Hemopurifier treatment data was presented at the American Society of Nephrology (ASN) Annual Meeting by Helmut Geiger, M.D., Chief of Nephrology at Goethe University, Frankfurt University Hospital. Dr. Geiger reported that 242 million Ebola viruses were captured within the Hemopurifier during treatment, a number verified by a post-treatment elution protocol. The elution protocol has since be repeated, which resulted in second measurement of 253 million copies of Ebola virus captured within the Hemopurifier.

Dr. Geiger also reported that the patient's viral load prior to the administration of a single 6.5-hour Hemopurifier treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). A post-treatment viral load measurement was reported to be 1,000 copies/ml. The treatment was well tolerated with no adverse events reported. At the time of treatment, the Ebola patient was comatose and suffering from multiple organ failure, which required mechanical ventilation, continuous dialysis and the administration of vasopressor medications. The patient made a full recovery and returned home to his family. A publication in the journal "Blood Purification" entitled, "Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease – First Experience with Lectin Affinity Plasmapheresis." can be accessed online at: http://www.karger.com/Article/Abstract/375229

Read this release in full at http://www.investorideas.com/CO/AEMD/news/2015/05131.asp

About Aethlon Medical, Inc.

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer promoting exosomes from the circulatory system of treated individuals. Our majority owned subsidiary Exosome Sciences, Inc., is advancing exosome-based liquid biopsies to diagnose and monitor Cancer and Chronic Traumatic Encephalopathy (CTE), a neurodegenerative disorder often found in individuals with a history of repetitive brain trauma.

About The Aethlon Hemopurifier®

Of the hundreds of viruses known to be infectious to man, antiviral drug therapies are approved for fewer than ten. The Aethlon Hemopurifier® provides a broad-spectrum therapeutic strategy to address drug resistant viral pathogens. To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus (Ebola), Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV). Time Magazine recently named the Hemopurifier to their list of 'Top 25 Inventions" and "The 11 Most Remarkable Advances in Healthcare." Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the capture of some of world's deadliest pathogens. These include: Dengue hemorrhagic fever, Lassa hemorrhagic fever, H5N1 avian influenza, H1N1 swine flu virus, the reconstructed 1918 influenza virus, West Nile virus and Vaccinia and Monkeypox, which serve as models for human smallpox infection. U.S. clinical progression of Hemopurifier therapy is being advanced under FDA approved clinical studies.

Aethlon is also investigating the use of Hemopurifier therapy to capture tumor-derived exosomes, a significant unaddressed therapeutic target in cancer care. Tumor-derived exosomes promote cancer progression through multiple mechanisms, which include seeding the spread of metastasis and direct suppression of the immune response. In regards to our therapeutic mechanism of action, the Hemopurifier incorporates a patented affinity technique that allows for selective binding to a unique structure that resides on the surface of tumor-derived exosomes and glycoproteins that coat infectious viruses. Additional information can be found online at www.AethlonMedical.com  or you can connect with us on on http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

James A. Joyce 
Chairman and CEO 
858.459.7800 x301 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer 
858.459.7800 x300 
jfrakes@aethlonmedical.com

David Zazoff 
MDM Worldwide Solutions 
646-403-3554

dzazoff@mdmworldwide.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.